-

Bruce Booth is a Partner at Atlas Venture focused on helping start and fund emerging biotech therapeutics companies. He's married to a wonderful woman and has three great kids. Active skier, runner, fly fisherman.
-
subscribe by email
twitter
- That said, "First-time" venture financings of new biotech are down however, and this is a concern. Need more new startups. #cvforum13 2 days ago
- Panel at #cvforum13 says Biotech VC funding at 95 levels. Not true. Overall biotech VC roughly stable for decade, w/ quarterly variation. 2 days ago
Recent Posts
current comments
- Friv 4 on Life Sciences: The Rodney Dangerfield of Venture Capital
- Observer on Welcoming Amgen & Novartis As Partners In Atlas IX
- Y8 on VC-backed Biotech Holding Periods: Tortoise or Hare?
- yepi8 on VC-backed Biotech Holding Periods: Tortoise or Hare?
- kizi2 on Life Sciences: The Rodney Dangerfield of Venture Capital
topics
- Atlas Venture (2)
- Biotech financing (10)
- Biotech investment themes (13)
- Biotech startup advice (8)
- Boston Cluster (7)
- Capital efficiency (13)
- Diagnostics (2)
- Exits IPOs M&As (29)
- General Venture Capital (25)
- New business models (14)
- Personalized Medicine (2)
- Pharma industry (23)
- Portfolio news (10)
- Translational research (3)
- Uncategorized (12)
- VC-backed Biotech Returns (33)
Monthly Archive
- May 2013 (3)
- April 2013 (2)
- March 2013 (4)
- February 2013 (1)
- January 2013 (3)
- December 2012 (3)
- November 2012 (4)
- October 2012 (3)
- September 2012 (4)
- August 2012 (3)
- July 2012 (3)
- June 2012 (4)
- May 2012 (3)
- April 2012 (2)
- March 2012 (3)
- February 2012 (3)
- January 2012 (6)
- December 2011 (4)
- November 2011 (4)
- October 2011 (3)
- September 2011 (4)
- August 2011 (3)
- July 2011 (4)
- June 2011 (4)
- May 2011 (5)
- April 2011 (8)
- March 2011 (10)
Category Archives: Biotech startup advice
Phil Needleman’s Ten Commandments of Drug R&D
March 27, 2013
Pharmaceutical R&D is a very low velocity, high cost process, which makes it hard for any individual to gather the large body of experience required to inform better decision-making. This is why pharma’s embedded institutional knowledge should be the source
Lessons Learned: Reflections On Early Stage Biotech Venture Investing
February 8, 2013
Venture capital is often called an apprenticeship business in large part because experience matters and takes time to accumulate. But successful firms are able to translate and transfer experiential wisdom through institutional memory, which involves codifying what works and what
Unleashing Biotech Innovation With The Currency of Entrepreneurship
December 5, 2012
The translation of cutting-edge science into new clinically-relevant therapeutics is the ultimate goal of many academic investigators, industry researchers, and investors. This stage of R&D is the most challenging, and typically frought with scientific and technical risks: taking a new
The Energetics of Fear and Greed in the Boardroom
October 25, 2012
Like many things driven by human nature, venture-backed biotech boardrooms often swing between the emotions of fear and greed. Fear of losing your shirt, or the greed of demanding more of the story than is warranted. It’s the age-old imbalance
Scientific Reproducibility: Begley’s Six Rules
September 26, 2012
The lack of robust reproducibility in the scientific literature is both shocking and troubling, and has been a widely covered topic over the past couple years. One of the earliest blogs here at LifeSciVC was on the dirty secret that
Biotech Scientific Advisory Boards: What Works, What Doesn’t
September 10, 2012
Almost every biotech has a Scientific Advisory Board, but few use them particularly well. Although SABs can be hugely valuable in helping shape a program or portfolio, or raising the visibility of a startup, they can also be a colossal
Venture Debt: Under-Appreciated Tool for Building Biotechs
July 11, 2012
Cash-burning R&D-stage biotechs have big appetites for cash, which is typically addressed with an equity-based diet. It’s also supported through corporate partnerships and other less dilutive means such as grants and foundation funding. But another important and often under-appreciated source
High-Performing Boards in Early Stage Biotech
March 3, 2012
Having a highly functional and productive Board of Directors is a key ingredient for success for most companies, but its of particular importance for early stage startups. The web is full of advice around what are the “best practices” for venture-backed



